Precipio, Inc. annual report, FY2013

Business Context and Reporting Period

The supplied filing is Transgenomic, Inc.’s Form 10-K for the fiscal year ended December 31, 2013—not a filing identified as Precipio, Inc. The company operated Laboratory Services and Genetic Assays and Platforms businesses, providing genetic testing, research services, instruments, and consumables. Unless otherwise noted, financial amounts below are in millions of dollars.

The filing also presents unaudited fourth-quarter results. A one-for-twelve reverse stock split became effective January 27, 2014; share and per-share figures were retrospectively adjusted.

Financial Performance and Position

Laboratory Services sales fell 20% to $15.4 million, principally on lower neurology testing volumes; Genetic Assays and Platforms sales were essentially flat at $12.2 million. Laboratory Services gross margin declined to 44% from 48%, while the other segment remained at 47%. Selling, general and administrative expense rose to $25.0 million, including a $3.0 million increase in bad-debt provision; research and development expense increased to $3.2 million.

Cash used in investing activities was $1.8 million and financing activities provided $7.4 million. Year-end total assets were $30.3 million, total liabilities and mezzanine equity were $18.8 million, and stockholders’ equity was $11.4 million. Debt was $6.6 million, including a $2.6 million revolving-line balance and a $4.0 million term loan. Contractual obligations totaled $13.7 million, including $6.6 million of debt principal, $1.0 million of scheduled interest, and $5.1 million of operating leases.

Changes, Outlook, and Risks

• Sales decreased 13% year over year, and gross margin fell three percentage points. The operating loss widened by $6.3 million.
• Receivables were affected by slower Laboratory Services collections and high fourth-quarter instrument shipments. The allowance for doubtful accounts rose to $3.8 million from $2.2 million; the 2013 provision was $5.5 million.
• Management stated that cash at year-end together with proceeds from a March 2014 preferred-stock financing was expected to fund operations for at least 12 months. The company subsequently raised approximately $7.0 million gross through Series B convertible preferred stock. The securities initially convert one-for-one into common shares, subject to adjustment, and carry a 6% cumulative annual dividend.
• The company was not in compliance with its minimum-liquidity covenant at December 31, 2013; lenders waived the default in January 2014. A March 2014 loan amendment suspended term-loan principal and interest payments through March 2015, with payments scheduled to resume April 1, 2015. The debt is secured by company assets and the agreement includes other restrictive covenants.
• Management highlighted commercialization partnerships for CardioPredict and oncology tests, and development of ICE COLD-PCR. These are strategic initiatives, not quantified financial guidance. The filing provides no clear numerical revenue or earnings forecast.
• Key risks include sustained losses and cash burn, reimbursement and test-volume pressures, bad debts and collection delays, dependence on financing and lender waivers, potential equity dilution, and competition. The company also cited laboratory certification and privacy requirements, supplier concentration for WAVE instruments, and intellectual-property risks. Pending ordinary-course claims were not expected by management to have a material adverse effect.
• The 2013 statements received an unqualified audit opinion. Management reported disclosure controls and internal control over financial reporting effective as of year-end; the auditor did not provide an internal-control attestation.

Important Facts for Investors to Verify

1. Confirm the correct issuer and filing: the supplied 10-K is for Transgenomic, Inc., although the request metadata names Precipio, Inc.
2. Review subsequent filings for actual cash use, collections, liquidity, and whether the March 2014 financing and lender amendments provided adequate runway.
3. Check compliance with the amended loan covenants, collateral terms, interest obligations, and the resumption of term-loan payments in April 2015.
4. Assess the collectability of receivables and the adequacy of bad-debt and contractual-reimbursement allowances.
5. Evaluate the dilution and economic terms of preferred stock, accumulated preferred dividends, warrants, and other potential share issuances.
6. Track whether commercial partnerships and ICE COLD-PCR development translated into measurable sales, margins, and cash generation.